Sakr Y, Payen D, Reinhart K, Sipmann F S, Zavala E, Bewley J, Marx G, Vincent J-L
Friedrich-Schiller-University, Jena, Germany.
Br J Anaesth. 2007 Feb;98(2):216-24. doi: 10.1093/bja/ael333.
The influence of hydroxyethyl starch (HES) solutions on renal function is controversial. We investigated the effect of HES administration on renal function in critically ill patients enrolled in a large multicentre observational European study.
All adult patients admitted to the 198 participating intensive care units (ICUs) during a 15-day period were enrolled. Prospectively collected data included daily fluid administration, urine output, sequential organ failure assessment (SOFA) score, serum creatinine levels, and the need for renal replacement therapy (RRT) during the ICU stay.
Of 3147 patients, 1075 (34%) received HES. Patients who received HES were older [mean (SD): 62 (SD 17) vs 60 (18) years, P = 0.022], more likely to be surgical admissions, had a higher incidence of haematological malignancy and heart failure, higher SAPS II [40.0 (17.0) vs 34.7 (16.9), P < 0.001] and SOFA [6.2 (3.7) vs 5.0 (3.9), P < 0.001] scores, and less likely to be receiving RRT (2 vs 4%, P < 0.001) than those who did not receive HES. The renal SOFA score increased significantly over the ICU stay independent of the type of fluid administered. Although more patients who received HES needed RRT than non-HES patients (11 vs 9%, P = 0.006), HES administration was not associated with an increased risk for subsequent RRT in a multivariable analysis [odds ratio (OR): 0.417, 95% confidence interval (CI): 0.05-3.27, P = 0.406]. Sepsis (OR: 2.03, 95% CI: 1.37-3.02, P < 0.001), cardiovascular failure (OR: 6.88, 95% CI: 4.49-10.56, P < 0.001), haematological cancer (OR: 2.83, 95% CI: 1.28-6.25, P = 0.01), and baseline renal SOFA scores > 1 (P < 0.01 for renal SOFA 2, 3, and 4 with renal SOFA = 0 as a reference) were all associated with a higher need for RRT.
In this observational study, haematological cancer, the presence of sepsis, cardiovascular failure, and baseline renal function as assessed by the SOFA score were independent risk factors for the subsequent need for RRT in the ICU. The administration of HES had no influence on renal function or the need for RRT in the ICU.
羟乙基淀粉(HES)溶液对肾功能的影响存在争议。我们在一项大型欧洲多中心观察性研究中,调查了给予HES对危重症患者肾功能的影响。
纳入在15天内入住198个参与研究的重症监护病房(ICU)的所有成年患者。前瞻性收集的数据包括每日液体输入量、尿量、序贯器官衰竭评估(SOFA)评分、血清肌酐水平以及ICU住院期间肾脏替代治疗(RRT)的需求。
3147例患者中,1075例(34%)接受了HES。接受HES的患者年龄更大[平均(标准差):62(标准差17)岁对60(18)岁,P = 0.022],更可能是外科手术入院患者,血液系统恶性肿瘤和心力衰竭的发生率更高,急性生理和慢性健康状况评分系统II(SAPS II)[40.0(17.0)对34.7(16.9),P < 0.001]和SOFA[6.2(3.7)对5.0(3.9),P < 0.001]评分更高,且与未接受HES的患者相比,接受RRT的可能性更小(2%对4%,P < 0.001)。在ICU住院期间,无论给予何种类型的液体,肾脏SOFA评分均显著增加。尽管接受HES的患者比未接受HES的患者需要RRT的更多(11%对9%,P = 0.006),但在多变量分析中,给予HES与后续RRT风险增加无关[比值比(OR):0.417,95%置信区间(CI):0.05 - 3.27,P = 0.406]。脓毒症(OR:2.03,95% CI:1.37 - 3.02,P < 0.001)、心血管衰竭(OR:6.88,95% CI:4.49 - 10.56,P < 0.001)、血液系统癌症(OR:2.83,95% CI:1.28 - 6.25,P = 0.01)以及基线肾脏SOFA评分>1(以肾脏SOFA = 0为参照,肾脏SOFA为2、3和4时P < 0.01)均与更高的RRT需求相关。
在这项观察性研究中,血液系统癌症、脓毒症的存在、心血管衰竭以及通过SOFA评分评估的基线肾功能是ICU中后续需要RRT的独立危险因素。给予HES对ICU中的肾功能或RRT需求没有影响。